NeuClone

[Available On-Demand]
Search General Info
Search Education
Search Partnering Companies
NeuClone is a clinical-stage biopharmaceutical company focused exclusively on developing and commercialising a pipeline of biosimilar monoclonal antibody (mAb) products for global registration.

NeuClone's pipeline consists of 20 biosimilars, six of which have been disclosed referencing Stelara (ustekinumab), Herceptin (trastuzumab), Perjeta (pertuzumab), Synagis (palivizumab), Prolia (denosumab) and Humira (adalimumab). The remaining 14 biosimilars can be disclosed under CDA.

NeuClone's Stelara and Herceptin biosimilars are undergoing clinical development. Additional biosimilars referencing Perjeta, Prolia, Synagis and more are undergoing manufacturing scale-up ahead of initiating clinical trials.

NeuClone is exploring potential partnerships for biosimilar mAbs through clinical development and commercialisation into North America, Europe and other selected developed world and emerging markets.
Company Type:
Company Website:
Company HQ State:
Not Provided
Company HQ Country:
Australia
Year Founded:
2007
Main Therapeutic Focus:
Lead Product in Development:
Stelara (ustekinumab) biosimilar 'NeuLara'
Development Phase of Primary Product:
Number Of Unlicensed Products (For Which You Are Seeking Partners):
15+
Speaker
photo
CEO, Founder and Director
NeuClone